Fianostics is awarded the Lower Austrian Innovation Price

Fianostics is awarded the Lower Austrian Innovation Price
The highly sensitive FluoBolt™-technology for the first time allows the simultaneous quantitative determination of anti S1-RBD and anti NC antibodies to SARS-Cov-2.This allows international comparison of the immune status of infected and vaccinated persons.

Results correlate perfectly to the international standards of NIBSC andWHO. Only 10µl of serum saples are necessary for this highly sensitive test system. The test complies to the latest IVDR und ISO 13485 specifications and is available for research as well as routine diagnostic applications.

ďalšie príspevky